Nonsteroidal Mineralocorticoid Receptor Antagonists: Exploring Role in Cardiovascular Disease

被引：1

作者：

Watson, Kristin ^{[1
,2
]}

Kukin, Alina ^{[3
]}

Wasik, Allie K. ^{[4
]}

Shulenberger, Christine E. ^{[5
]}

机构：

[1] Univ Maryland, Dept Pharm Practice & Sci, Sch Pharm, Baltimore, MD 21201 USA

[2] ATRIUM Cardiol Collaborat, Baltimore, MD USA

[3] Hosp Univ Penn, Dept Pharm, 3400 Spruce St, Philadelphia, PA 19104 USA

[4] Northwestern Mem Hosp, Bluhm Cardiovasc Inst, Dept Pharm, Chicago, IL 60611 USA

[5] Penn State Hlth Milton S Hershey Med Ctr, Dept Pharm, Hershey, PA USA

来源：

JOURNAL OF CARDIOVASCULAR PHARMACOLOGY | 2021年 / 77卷 / 06期

关键词：

heart failure; mineralocorticoid receptor antagonists; antagonists; aldosterone receptor; diabetes mellitus; type; 2/complications; hypertension; CONGESTIVE-HEART-FAILURE; ANGIOTENSIN-ALDOSTERONE SYSTEM; LEFT-VENTRICULAR DYSFUNCTION; CONVERTING ENZYME-INHIBITOR; FINERENONE VS. EPLERENONE; BASE-LINE CHARACTERISTICS; ASSOCIATION TASK-FORCE; DOUBLE-BLIND; ESAXERENONE CS-3150; EJECTION FRACTION;

D O I：

10.1097/FJC.0000000000000990

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Aldosterone, a mineralocorticoid hormone, plays a role in the pathophysiology of many cardiovascular disease states. Mineralocorticoid receptor antagonists (MRAs) have been shown to improve clinical outcomes in select patient populations. However, use of available steroidal receptor antagonists, eplerenone and spironolactone, is often limited by the risk or development of hyperkalemia. Nonsteroidal MRAs have been designed to overcome this limitation. The nonsteroidal MRAs have been studied in patients with heart failure with reduced ejection fraction, hypertension, and to lower the risk of cardiac and renal outcomes in those with type 2 diabetes and renal disease. In this review, the pharmacology of the MRAs is compared, the data evaluating the use of nonsteroidal MRAs are examined, and the place of this new generation of therapy is discussed. At this time, it seems that there could be a future role for nonsteroidal MRAs to reduce the risk of renal outcomes in high-risk individuals

引用

页码：685 / 698

页数：14

共 122 条

[1]

Abdallah JG, 2001, J AM SOC NEPHROL, V12, P1335, DOI 10.1681/ASN.V1271335

[2]

ABSHAGEN U, 1976, N-S ARCH PHARMACOL, V296, P37, DOI 10.1007/BF00498838

[3] Use of Aldosterone Antagonists in Heart Failure [J].

Albert, Nancy M. ;

Yancy, Clyde W. ;

Liang, Li ;

Zhao, Xin ;

Hernandez, Adrian F. ;

Peterson, Eric D. ;

Cannon, Christopher P. ;

Fonarow, Gregg C. .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (15) :1658-1665

[4] Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1 [J].

Amazit, Larbi ;

Le Billan, Florian ;

Kolkhof, Peter ;

Lamribet, Khadija ;

Viengchareun, Say ;

Fay, Michel R. ;

Khan, Junaid A. ;

Hillisch, Alexander ;

Lombes, Marc ;

Rafestin-Oblin, Marie-Edith ;

Fagart, Jerome .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2015, 290 (36) :21876-21889

[5] Anti-albuminuric effect of the aldosterone blocker eplerenone in non-diabetic hypertensive patients with albuminuria: a double-blind, randomised, placebo-controlled trial [J].

Ando, Katsuyuki ;

Ohtsu, Hiroshi ;

Uchida, Shunya ;

Kaname, Shinya ;

Arakawa, Yoshihiro ;

Fujita, Toshiro .

LANCET DIABETES & ENDOCRINOLOGY, 2014, 2 (12) :944-953

[6]

[Anonymous], 2012, DIABETES CARE, V35, pS11, DOI [10.2337/dc12-s004, 10.2337/dc35-S011]

[7]

[Anonymous], 2018, ALD SPIR PACK INS

[8]

[Anonymous], EX COLL DAIICH SANK

[9]

[Anonymous], 2008, INSPR EPL PACK INS

[10] Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist [J].

Arai, Kiyoshi ;

Homma, Tsuyoshi ;

Morikawa, Yuka ;

Ubukata, Naoko ;

Tsuruoka, Hiyoyuki ;

Aoki, Kazumasa ;

Ishikawa, Hirokazu ;

Mizuno, Makoto ;

Sada, Toshio .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2015, 761 :226-234

← 1 2 3 4 5 6 7 8 9 10 →